PMID- 36473632
OWN - NLM
STAT- MEDLINE
DCOM- 20230110
LR  - 20240318
IS  - 2210-741X (Electronic)
IS  - 2210-7401 (Linking)
VI  - 47
IP  - 1
DP  - 2023 Jan
TI  - Comparison of the effects of lenvatinib and sorafenib on survival in patients 
      with advanced hepatocellular carcinoma: A systematic review and meta-analysis.
PG  - 102061
LID - S2210-7401(22)00194-2 [pii]
LID - 10.1016/j.clinre.2022.102061 [doi]
AB  - BACKGROUND AND AIM: The first-line systemic therapy for advanced hepatocellular 
      carcinoma (HCC) involves the use of sorafenib and lenvatinib. The present 
      meta-analysis attempted to compare the therapeutic safety and effectiveness of 
      the two drugs in advanced HCC. METHODS: The library databases of Cochrane, 
      Embase, PubMed, and Web of Science were systematically searched to identify 
      eligible studies comparing the long-term outcomes of sorafenib and lenvatinib use 
      in advanced HCC patients. Overall survival (OS) was considered the primary 
      endpoint, whereas the progression-free survival (PFS), severe adverse events 
      (AEs), objective response rate (ORR), and disease control rate (DCR) were 
      considered the secondary endpoints. RESULTS: The present systematic review 
      included 8 nonrandomized studies and 1 randomized controlled trial, comprising a 
      total of 1, 914 cases. OS in patients receiving lenvatinib was better than that 
      in patients receiving sorafenib [hazard ratio (HR): 1.23; 95% confidence interval 
      (CI): 1.04-1.45]. Additionally, patients who received lenvatinib exhibited better 
      PFS, ORR, and DCR (HR: 0.89, 95% CI: 0.79-0.99), [odds ratio (OR: 7.50, 95% CI: 
      4.43-12.69)], (OR: 7.50, 95% CI: 4.43-12.69), but higher incidences of AEs than 
      those receiving sorafenib (OR: 1.28, 95% CI: 1.08-1.53). CONCLUSION: Lenvatinib 
      is superior to sorafenib in treating unresectable HCC patients.
CI  - Copyright (c) 2022 Elsevier Masson SAS. All rights reserved.
FAU - Hu, Lingbo
AU  - Hu L
AD  - Department of Hepatopancreatobiliary Surgery, Taizhou Hospital of Zhejiang 
      Province affiliated to Wenzhou Medical University, Zhejiang, China; Department of 
      Hepatopancreatobiliary Surgery, Enze Hospital, Taizhou Enze Medical Center 
      (Group), Zhejiang, China.
FAU - Zheng, Yu
AU  - Zheng Y
AD  - Department of Rehabilitation Medicine, the First Affiliated Hospital of Nanjing 
      Medical University, Jiangsu, China.
FAU - Lin, Jiangyin
AU  - Lin J
AD  - Department of Blood Purification, Taizhou Hospital of Zhejiang Province 
      affiliated to Wenzhou Medical University, Zhejiang, China.
FAU - Shi, Xingpeng
AU  - Shi X
AD  - Department of Hepatopancreatobiliary Surgery, Taizhou Hospital of Zhejiang 
      Province affiliated to Wenzhou Medical University, Zhejiang, China; Department of 
      Hepatopancreatobiliary Surgery, Enze Hospital, Taizhou Enze Medical Center 
      (Group), Zhejiang, China.
FAU - Wang, Aidong
AU  - Wang A
AD  - Department of Hepatopancreatobiliary Surgery, Taizhou Hospital of Zhejiang 
      Province affiliated to Wenzhou Medical University, Zhejiang, China; Department of 
      Hepatopancreatobiliary Surgery, Enze Hospital, Taizhou Enze Medical Center 
      (Group), Zhejiang, China. Electronic address: wangaidong@enzemed.com.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
DEP - 20221205
PL  - France
TA  - Clin Res Hepatol Gastroenterol
JT  - Clinics and research in hepatology and gastroenterology
JID - 101553659
RN  - 0 (Antineoplastic Agents)
RN  - EE083865G2 (lenvatinib)
RN  - 0 (Phenylurea Compounds)
RN  - 9ZOQ3TZI87 (Sorafenib)
SB  - IM
MH  - Humans
MH  - *Antineoplastic Agents/adverse effects
MH  - *Carcinoma, Hepatocellular/pathology
MH  - *Liver Neoplasms/pathology
MH  - Phenylurea Compounds/therapeutic use
MH  - Sorafenib/therapeutic use
MH  - Controlled Clinical Trials as Topic
OTO - NOTNLM
OT  - Advanced
OT  - Hepatocellular carcinoma
OT  - Lenvatinib
OT  - Meta-analysis
OT  - Sorafenib
OT  - Unresectable
COIS- Declaration of Competing Interests The authors declare that they have no known 
      competing financial interests or personal relationships that could have appeared 
      to influence the work reported in this paper.
EDAT- 2022/12/07 06:00
MHDA- 2023/01/11 06:00
CRDT- 2022/12/06 19:25
PHST- 2022/07/09 00:00 [received]
PHST- 2022/12/02 00:00 [accepted]
PHST- 2022/12/07 06:00 [pubmed]
PHST- 2023/01/11 06:00 [medline]
PHST- 2022/12/06 19:25 [entrez]
AID - S2210-7401(22)00194-2 [pii]
AID - 10.1016/j.clinre.2022.102061 [doi]
PST - ppublish
SO  - Clin Res Hepatol Gastroenterol. 2023 Jan;47(1):102061. doi: 
      10.1016/j.clinre.2022.102061. Epub 2022 Dec 5.